Peroxisome Proliferator-activated Receptors and Hepatic Stellate Cell Activation
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
The present study examined the roles of peroxisome proliferator-activated receptors (PPAR) in activation of hepatic stellate cells (HSC), a pivotal event in liver fibrogenesis. RNase protection assay detected mRNA for PPARgamma1 but not that for the adipocyte-specific gamma2 isoform in HSC isolated from sham-operated rats, whereas the transcripts for neither isoforms were detectable in HSC from cholestatic liver fibrosis induced by bile duct ligation (BDL). Semi-quantitative reverse transcriptase-polymerase chain reaction confirmed a 70% reduction in PPARgamma mRNA level in HSC from BDL. Nuclear extracts from BDL cells showed an expected diminution of binding to PPAR-responsive element, whereas NF-kappaB and AP-1 binding were increased. Treatment of cultured-activated HSC with ligands for PPARgamma (10 microm 15-deoxy-Delta(12,14)-PGJ(2) (15dPGJ(2)); 0.1 approximately 10 microm BRL49653) inhibited DNA and collagen synthesis without affecting the cell viability. Suppression of HSC collagen by 15dPGJ(2) was abrogated 70% by the concomitant treatment with a PPARgamma antagonist (GW9662). HSC DNA and collagen synthesis were inhibited by WY14643 at the concentrations known to activate both PPARalpha and gamma (>100 microm) but not at those that only activate PPARalpha (<10 microm) or by a synthetic PPARalpha-selective agonist (GW9578). 15dPGJ(2) reduced alpha1(I) procollagen, smooth muscle alpha-actin, and monocyte chemotactic protein-1 mRNA levels while inducing matrix metalloproteinase-3 and CD36. 15dPGJ(2) and BRL49653 inhibited alpha1(I) procollagen promoter activity. Tumor necrosis factor alpha (10 ng/ml) reduced PPARgamma mRNA, and this effect was prevented by the treatment with 15dPGJ(2). These results demonstrate that HSC activation is associated with the reductions in PPARgamma expression and PPAR-responsive element binding in vivo and is reversed by the treatment with PPARgamma ligands in vitro. These findings implicate diminished PPARgamma signaling in molecular mechanisms underlying activation of HSC in liver fibrogenesis and the potential therapeutic value of PPARgamma ligands for liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![FIG. 4 A , PPAR g (15dPGJ2, BRL49653) ligands inhibit HSC DNA and collagen synthesis. The 3-4-day primary cultures of HSC were exposed to 15dPGJ2 (1 and 10 m M), BRL49653 (1 and 10 m M), or WY14643 (10 ; 250 m M) for 18 h, and [ 3 H]thymidine incorporation into DNA was assessed. Note a significant, ; 40%, inhibition in HSC DNA synthesis by 15dPGJ2 and BRL49653 at 10 m M and WY14643 at 100 and 250 m M. *, p , 0.05; **, p , 0.01 compared with the respective control. DMSO , Me2SO. B , collagen production by cultured HSC, as determined by incorporation of [ 3 H]proline into collagenase-sensitive peptides was significantly inhibited by 18 h of treatment with 15dPGJ 2 (10 m M), BRL49653 (0.1 ; 10 m M), and WY14643 (100 m M). *, p , 0.05; **,](https://figures.cochat.ai/paper-figures/a66e36c4743842c5bde9349747bed49a/peroxisome-proliferator-activated-receptors-and-hepatic-stellate-cell-activation-figure-4.png)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“bezafibrate, a broad peroxisome proliferator-activated receptor (PPAR) agonist with anticholestatic, 14 anti-inflammatory, 15 and antifibrotic 16 properties”
From Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial (2021) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“HSC activation is therefore associated with low levels of PPAR-γ expression, and the assumed relation between PPAR-γ and liver fibrosis was confirmed in an experimental restoration of PPAR-γ levels in HSCs, which resulted in a regression of aHSCs to quiescence state.[126,127]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Schreiber, E., Matthias, P., Müller, M. M., & Schaffner, W. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.15.6419 · Cited by 4,179
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Self-citationThomas, A. C., & Campbell, J. H. (2000) · Cited by 2,800
A human retinoic acid receptor which belongs to the family of nuclear receptors
Petkovich, M., Brand, N. J., Krust, A., & Chambon, P. (1987) · Nature · doi:10.1038/330444a0 · Cited by 2,214
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816
Self-citationPPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797
The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment Strategies
Flier, J. S., Underhill, L. H., & Friedman, S. L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306243282508 · Cited by 1,432
The PPARα–leukotriene B4 pathway to inflammation control
Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., & Santoro, M. G. (2000) · Nature · doi:10.1038/47520 · Cited by 1,310
Adipogenesis and Obesity: Rounding Out the Big Picture
Spiegelman, B. M., & Flier, J. S. (1996) · Cell · doi:10.1016/s0092-8674(00)81359-8 · Cited by 1,269
Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
Staels, B., Koenig, W., Habib, A., Merval, R., Lebret, M., Torra, I. P., Delerive, P., Fadel, A., Chinetti, G., Fruchart, J.-C., et al. (1998) · Nature · doi:10.1038/31701 · Cited by 1,134
Abumrad, N. A., el-Maghrabi, M. R., Amri, E. Z., Lopez, E., & Grimaldi, P. A. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)46753-6 · Cited by 1,002
The Retinoids-Biology, Chemistry and Medicine
Wolf, G. (1994) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/60.5.796a · Cited by 998
Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase
Huang, J. T., Welch, J. S., Ricote, M., Binder, C. J., Willson, T. M., Kelly, C., Witztum, J. L., Funk, C. D., Conrad, D., & Glass, C. K. (1999) · Nature · doi:10.1038/22572 · Cited by 855
Self-citationA novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response
Su, C. G., Wen, X., Bailey, S. T., Jiang, W., Rangwala, S. M., Keilbaugh, S. A., Flanigan, A., Murthy, S., Lazar, M. A., & Wu, G. D. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7145 · Cited by 767
CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells
Dawson, D. W., Pearce, S. F. A., Zhong, R., Silverstein, R. L., Frazier, W. A., & Bouck, N. P. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.138.3.707 · Cited by 676
Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.
Vidal-Puig, A., Jimenez-Liñan, M., Lowell, B. B., Hamann, A., Hu, E., Spiegelman, B., Flier, J. S., & Moller, D. E. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118703 · Cited by 655
Camp, H. S., & Tafuri, S. R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.16.10811 · Cited by 446
Maher, J. J., & McGuire, R. F. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114886 · Cited by 423
Fadok, V. A., Warner, M. L., Bratton, D. L., & Henson, P. M. (1998) · PubMed · Cited by 406
Juge-Aubry, C., Pernin, A., Favez, T., Burger, A. G., Wahli, W., Meier, C. A., & Desvergne, B. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25252 · Cited by 378
Nakatsukasa, H., Nagy, P., Evarts, R. P., Hsia, C. C., Marsden, E., & Thorgeirsson, S. S. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114643 · Cited by 355
Fadok, V. A., Warner, M. L., Bratton, D. L., & Henson, P. M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.11.6250 · Cited by 354
Friedman, E. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304223281620 · Cited by 342
Zhang, B. (1996) · Molecular Endocrinology · doi:10.1210/me.10.11.1457 · Cited by 332
The hepatic stellate (Ito) cell: its role in human liver disease
Hautekeete, M. L., & Geerts, A. (1997) · Virchows Archiv · doi:10.1007/bf01324802 · Cited by 307
Wong, L., Yamasaki, G., Johnson, R. J., & Friedman, S. L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117497 · Cited by 304
HNE interacts directly with JNK isoforms in human hepatic stellate cells.
Parola, M., Robino, G., Marra, F., Pinzani, M., Bellomo, G., Leonarduzzi, G., Chiarugi, P., Camandola, S., Poli, G., Waeg, G., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1413 · Cited by 297
Qi, Z., Atsuchi, N., Ooshima, A., Takeshita, A., & Ueno, H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2345 · Cited by 288
Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo.
Rockey, D. C., Housset, C. N., & Friedman, S. L. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116769 · Cited by 268
Castrillo, A., Díaz-Guerra, M. J. M., Hortelano, S., Martín-Sanz, P., & Boscá, L. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.5.1692-1698.2000 · Cited by 264
Kim, Y., Ratziu, V., Choi, S.-G., Lalazar, A., Theiss, G., Dang, Q., Kim, S.-J., & Friedman, S. L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.50.33750 · Cited by 249
Bachem, M. G., Meyer, D., Melchior, R., Sell, K. M., & Gressner, A. M. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115561 · Cited by 232
Rockey, D. C., & Chung, J. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118925 · Cited by 199
Salbert, G. (1993) · Molecular Endocrinology · doi:10.1210/me.7.10.1347 · Cited by 159
Cytokine Regulation of Hepatic Stellate Cells in Liver Fibrosis
Tsukamoto, H. (1999) · Alcoholism: Clinical & Experimental Research · doi:10.1097/00000374-199905000-00021 · Cited by 156
Self-citationFriedman, S. L., Yamasaki, G., & Wong, L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34095-4 · Cited by 150
Expression of Interleukin-10 by in Vitro and in Vivo Activated Hepatic Stellate Cells
Wang, S. C., Ohata, M., Schrum, L., Rippe, R. A., & Tsukamoto, H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.1.302 · Cited by 150
Self-citationDavis, B. H., Kramer, R. T., & Davidson, N. O. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114943 · Cited by 148
Okuno, M. (1997) · Hepatology · doi:10.1053/jhep.1997.v26.pm0009328313 · Cited by 141
Carloni, V., Romanelli, R. G., Pinzani, M., Laffi, G., & Geñtilini, P. (1997) · Gastroenterology · doi:10.1053/gast.1997.v112.pm9024306 · Cited by 128
Iredale, J. P., Goddard, S., Murphy, G., Benyon, R. C., & Arthur, M. J. P. (1995) · Clinical Science · doi:10.1042/cs0890075 · Cited by 110
Sp1 binding activity increases in activated Ito cells
Rippe, R. A., Almounajed, G., & Brenner, D. A. (1995) · Hepatology · doi:10.1002/hep.1840220135 · Cited by 102
Self-citationYee, H. F. (1998) · Hepatology · doi:10.1002/hep.510280336 · Cited by 82
Self-citationOhata, H., Ujike, Y., & Momose, K. (1997) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1997.272.6.c1980 · Cited by 70
Graf, K., Xi, X.-P., Hsueh, W. A., & Law, R. E. (1997) · FEBS Letters · doi:10.1016/s0014-5793(96)01371-3 · Cited by 70
Pan, L., Eckhoff, C., & Brinckerhoff, C. E. (1995) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240570402 · Cited by 67
All- trans and 9- cis retinoic acid alter rat hepatic stellate cell phenotype differentially
Hellemans, K., Grinko, I., Rombouts, K., Schuppan, D., & Geerts, A. (1999) · Gut · doi:10.1136/gut.45.1.134 · Cited by 66
Matsuoka, M., Zhang, M. Y., & Tsukamoto, H. (1990) · Hepatology · doi:10.1002/hep.1840110204 · Cited by 59
Self-citationImai, S., Okuno, M., Moriwaki, H., Muto, Y., Murakami, K., Shudo, K., Suzuki, Y., & Kojima, S. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00673-x · Cited by 55
Guo, X. W., Merlin, D., Laboisse, C., & Hopfer, U. (1997) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1997.273.3.c804 · Cited by 46
Egger, N. G., Schoenecker, J. A., Gourley, W. K., Motamedi, M., Anderson, K. E., & Weinman, S. A. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80260-7 · Cited by 40
Connective Tissue Metabolism and Hepatic Fibrosis: An Overview
Bissell, D. M. (1990) · Seminars in Liver Disease · doi:10.1055/s-2008-1040491 · Cited by 17
Velosa, J., Serejo, F., Saraiva, A. M., Marinho, R. T., Ramalho, F. J., & de Moura, M. C. (1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90203-4 · Cited by 7
Research works printed but not linked: 9
- Friedman, S. L., Wei, S., and Blaner, W. S. (1993) Am. J. Physiol. 264, G947-G952
- Tsukamoto, H., Cheng, S., and Blaner, W. S. (1996) Am. J. Physiol. 270, G581-G586
- Salbert, G., Fanjul, A., Piedrafita, F. J., Lu, X. P., Kim, S. J., Tran, P., and Pfahl, M. (1993) Mol. Endocrinol. 7, 1347-1356
- Okuno, M., Moriwaki, H., Imai, S., Muto, Y., Kawada, N., Suzuki, Y., and Kojima, S. (1997) Hepatology 26, 913-921
- Potter, J. J., Womack, L., Mezey, E., and Anania, F. A. (1998) Biochem. Cell Biol.244, 178 -182
- Lin, M., Rippe, R. A., Niemela, O., Brittenham, G., and Tsukamoto, H. (1997) Am. J. Physiol. 272, G1355-G1364
- Rippe, R. A., Almounajed, G., and Brenner, D. A. (1995) Hepatology 22, 241-251
- Zhang, B., Berger, J., Hu, E., Szalkowski, D., White-Carrington, S., Spiegelman, B. M., and Moller, D. E. (1996) Mol. Endocrinol. 10, 1457-1466
- Tsukamoto, H. (1999) Alcohol Clin. Exp. Res. 23, 911-916 · doi:10.1111/j.1530-0277.1999.tb04202.x · Paper page
Cited by
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
“Third, stellate cell activation is associated with downregulation of PPARg signaling, and ligands of PPARg but not PPARa downregulate stellate cell activation[57,58].”
BackgroundLiver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295
Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., & Bacon, B. R. (2003) · Hepatology · doi:10.1002/hep.1840380427 · Cited by 751
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 611
“Other molecular mechanisms involved in fibrosis include PPAR isoforms; experimental work concluded that suppression of PPARγ is required for HSC activation (206), with ligands for PPARγ reverting the activated phenotype of HSCs in vitro and abrogating fibrosis in vivo (207).”
Background
Metadata
- Authors
- Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H.
- Affiliations
- University of Southern California (US)
- University of North Carolina at Chapel Hill (US)
- University of California, Los Angeles (US)
- University of Maryland, College Park (US)
- Corresponding author
- Tsukamoto, Hidekazu
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-11
- Volume
- 275
- Issue
- 46
- Pages
- 35715-35722
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2025657436
- Cited by
- 473
- References
- 56
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 8 · 2023: 9 · 2022: 12 · 2021: 17 · 2020: 18 · 2019: 14 · 2018: 14 · 2017: 19 · 2016: 16 · 2015: 22 · 2014: 21 · 2013: 17 · 2012: 25
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 7274 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Veterans Affairs
- University of Southern California (DK48522)
- National Institutes of Health (5k08dk002450-05, AA10459)
- National Institute on Alcohol Abuse and Alcoholism (AA10459, R37AA006603, R37-AA-06603, P50AA011999)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-02450)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- peroxisome proliferator-activated receptors, PPARγ, hepatic stellate cell activation, liver fibrosis, cholestatic liver fibrosis, bile duct ligation, PPAR ligands, collagen synthesis, PPAR-responsive element, TNF-α, matrix metalloproteinase-3
- MeSH terms
- Rosiglitazone, Animals, Cell Survival, Cells, Cultured, Collagen, DNA, Gene Expression Regulation, Liver, Liver Cirrhosis, Biliary, Liver Cirrhosis, Experimental, Male, Promoter Regions, Genetic, Protein Binding, Pyrimidines, RNA, Messenger, Thiazoles, Transcription Factors, Tumor Necrosis Factor-alpha, Prostaglandin D2, Rats, Wistar, Receptors, Cytoplasmic and Nuclear, Protein Isoforms, Thiazolidinediones, Cell Size, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.